PlanetRx finds no cure, will liquidate assets

Struggling online drugstore Inc.'s board of directors has approved a plan to liquidate all the company's assets, including its Memphis distribution center.

A spokeswoman for PlanetRx said the company was shutting down entirely.

"After months of deliberations and evaluations,'s board of directors has concluded that a plan of liquidation presents the best option to preserve remaining shareholder value," Chairman and CEO Michael Beindorff said in a statement. "Therefore, it is in the best interest of our shareholders to develop a plan for the disposition of's assets in an orderly and efficient manner."

In recent weeks, PlanetRx put several domain names up for sale under the Web site. In January, was delisted from the Nasdaq Stock Market because the price of its stock dropped below US$1. The company didn't fight the delisting.

Yesterday's announcement comes just about a month after PlanetRx said it was closing its retail store and referring consumers to former rival Inc. in Bellevue, Wash. The company said it would focus on selling specialty drugs for cancer and HIV patients, and organ-transplant recipients.

At that time, PlanetRx also said it was planning to acquire a specialty pharmacy business, whose name it was to release in February.

The company had hoped it could stay afloat by moving into an area with bigger margins and where there is no dominant player.

But Liz Boehm, an analyst at Forrester Research said PlanetRx officials apparently decided that plan wouldn't work.

"They took a hard look and decided with their assets they wouldn't be bringing anything new, unique, or unusual into that new business," she said.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about drugstore.comForrester ResearchPlanetRx

Show Comments